Shoreline Biosciences Appoints Scott Forrest, PH.D., as Chief Business Officer

“We’re thrilled to welcome Scott to Shoreline as Chief Business Officer,” said Kleanthis G. Xanthopoulos, Ph.D., Chairman and CEO. “Scott is a highly accomplished executive with extensive experience in building and advancing emerging biotech companies and we look forward to leveraging his background as we evolve into a leading cell therapy company.”

Prior to joining Shoreline, Dr. Forrest was Chief Financial Officer of Autobahn Therapeutics where he was responsible for corporate development, portfolio planning and financial strategy. Prior to Autobahn, Dr. Forrest served as Chief Operating Officer and Chief Financial Officer at Inception Therapeutics, a Versant Ventures discovery engine focused on building and operating transformative biotech companies. In this role, he played an integral leadership role in multiple companies including Lycia Therapeutics, Pipeline Therapeutics, Chinook Therapeutics and Ventus Therapeutics. Prior to Inception, Dr. Forrest was a Co-Founder and Vice President of Operations and Corporate Development at BlackThorn Therapeutics. Earlier, he was Vice President of Business Development at The Scripps Research Institute, where he oversaw the creation and launch of more than 15 new biotech companies and led the negotiation and management of over $200 million in corporate alliances. He also held director or board observer positions with several companies including Zyngenia, Abide, Padlock and Epic Sciences. Dr. Forrest started his career at the University of North Carolina where he led the restructuring, expansion and management of the life sciences licensing team. He also served as an entrepreneur in residence at UNC and was a central part of the successful launch of multiple startup companies such as Epizyme. Dr. Forrest holds a B.S. in biochemistry from the University of Calgary and a Ph.D. in pharmacology from the University of Virginia.

“Shoreline is a highly innovative company with a differentiated approach to creating off-the-shelf immunotherapies that overcome the limitations of first-generation cell therapy products,” added Dr. Forrest. “The company’s history of building significant alliances, coupled with its blue-chip investors, accomplished team and breadth of its platform, make this a compelling opportunity. I’m very excited to join the team and look forward to contributing to Shoreline’s growth and continued success.”

For more information, please visit https://shorelinebio.com/ and engage with us on LinkedIn.

Shoreline Biosciences Investor and Media Contact:
Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243

Shoreline Biosciences Appoints Co-Founder William Sandborn, M.D. as Chief Medical Officer

Shoreline Biosciences, Inc. (Shoreline),a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targetedcellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, today announced the appointment of William Sandborn, M.D. as Chief Medical Officer. Dr. Sandborn is a world-renown award winning key opinion leader, inflammatory diseaseclinician, and scientific co-founder of multiple biotechnology companies.

“Bill has been an instrumental part in launching Shoreline as a co-founder and we are thrilled to announce his appointment to our leadership team as Chief Medical Officer,” said Kleanthis G. Xanthopoulos, Ph.D., Shoreline Co-Founder and Executive Chairman. “Bill’s depth and breadth of experience in the immunotherapy space will help us drive our cell therapy programs to the clinic and build a valuable pipeline of allogeneic iPSC-based therapies.”

Dr. Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda, California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester, Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011, he became a tenured Professor of Medicine, Chief of the Division of Gastroenterology, and Director of the Inflammatory Bowel Disease Center at the University of California San Diego. In 2019, he was awarded the Sherman Prize for his work in inflammatory bowel disease. He was a scientific co-founder of Santarus (acquired by Salix Pharmaceuticals for $2.6B in 2013, now Bausch Health), and currently chairs the Scientific Advisory Board for Prometheus Biosciences, Inc.Dr. Sandborn has published over 849 peer-reviewed articles.

“At Shoreline, we aim to take immunotherapies to the next level by harnessing the cutting-edge science of cell therapy to deliver improved therapeutic options to clinicians and their patients,” added Dr. Sandborn. “I’m very excited to be involved at the ground floor of Shoreline and look forward to translating my clinical and academic expertise into my new role as Chief Medical Officerto create transformative new cell therapies.”

For more information, please engage with us on LinkedIn.

Shoreline Biosciences Investor and Media
Contact: Amy Conrad Juniper
Pointamy@juniper-point.com
858-366-3243

Shoreline Biosciences Announces $43m Financing to Advance Pipeline of Allogeneic Natural Killer and Macrophage Cellular Immunotherapies Derived from Pluripotent Stem Cells

Shoreline Biosciences, Inc. (Shoreline),a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, today announced the completion of a $43M capital raise. The financing was led by Boxer Capital, with participation from BVF Partners L.P., Commodore Capital, Cormorant Capital, Janus Henderson Investors, Logos Capital, Kite,a Gilead company,and Wedbush Healthcare Partners,in addition to Stork Capital, and other investors. In connection with the financing, Christopher Fuglesang, Ph.D., J.D.from Boxer Capital, joined the Shoreline Board of Directors.

The proceeds from the financing will allow Shoreline to accelerate the advancement of its proprietary iPSCplatform focused on developing next generation NKcell and macrophage-cell therapies, while also supporting research efforts to create potent and persistent NK cell-specific Chimeric Antigen Receptors (CARs), switchable CAR-NK cell engagers and macrophage-specific CARs. In addition, Shoreline has entered into a strategic relationship with the Advanced Cell Therapy Laboratory of UC San Diego, a well-recognized manufacturing partner, to secure GMP manufacturing of Shoreline’s cell therapy products.

“We are thrilled to have the support of such outstanding investors who share our vision and commitment to build a differentiated and exciting cell therapy company with the ambition to lead the next wave of allogeneic, off-the-self, targeted and standardized cell therapies,” said Kleanthis G. Xanthopoulos, Ph.D., Shoreline Co-Founder and Executive Chairman. “With this financing, we are well-positioned to drive our programs to the clinic in multiple indications and to build a domain-dominant cell therapy company.”

“We look to invest in companies that are pushing that boundaries of scientific innovation and Shoreline is doing exactly that. Their approach to intelligently designing IPSC-derived cell therapies will help solve many of the current challenges with cell therapies,”said Christopher Fuglesang, Ph.D., J.D., co-founder and Managing Director of Boxer Capital.

Shoreline Biosciences was co-founded by renowned cell therapy expert Dan Kaufman, M.D., Ph.D., and biotech veterans Steven Holtzman, William Sandborn, M.D. and Kleanthis G. Xanthopoulos, Ph.D.


For more information: Please engage with us on LinkedIn.

Shoreline Biosciences Investor and Media

Contact: Amy Conrad Juniper
Pointamy@juniper-point.com
858-366-3243

info@shorelinebio.com
858-997-2703